🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Comenzamos la Reunión Anual de GELTAMO con el simposio satélite “Avances en el Manejo Multidisciplinar del Síndrome Linfoproliferativo Postrasplante”. Gran asistencia, ponencias de alto nivel y discusiones enriquecedoras. #GELTAMO2025

Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology annalsofoncology.org/article/S0923-…

#NotaDePrensaSEHH | Los hematólogos españoles marcan el futuro de los linfomas: 29.000 casos registrados y 13 ensayos clínicos en marcha ➕Consulta la nota aquí: sehh.es/sala-prensa/no… #HematoEnRed #HematoAvanza #SEHHematología #linfoma #cáncersanguineo

Immunotherapy response: is it all in the DLBCL-IQs? ashpublications.org/blood/article/…

CONGRESS | #EHA2025 | POSTER Gareth P. Gregory Gareth Gregory Monash University shares updated efficacy and safety of Glofit-GemOx vs R-GemOx in pts with R/R DLBCL after ≥1 LOT after 2-year follow up of the phase III STARGLO trial. Glofit-GemOx continued to confer a superior OS,

CONGRESS | #EHA2025 | PRESENTATION Raul Cordoba Raul Cordoba, MD, PhD Fundación Jiménez Díaz presents the first efficacy and safety results for epcoritamab in combination with R-ICE in patients with R/R DLBCL eligible for ASCT from the EPCORE NHL-2 trial (N = 31). Epcoritamab + R-ICE

CONGRESS | #EHA2025 | PRESENTATION Daniel Kerr, Tampa General Hospital Tampa General Cancer Institute, presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5 trial (N = 37). Fixed-duration epcoritamab + pola-R-CHP in patients with newly diagnosed

CONGRESS | #EHA2025 | PRESENTATION Talha Munir, LeedsCancerCentre, shares findings from the FLAIR study of MRD-guided Ibr+Ven vs Ibr monotherapy vs FCR in CLL (N=786). Ibr+Ven demonstrated superiority of PFS (93.9% vs 58.1% vs 79.0%) and OS (95.9% vs 86.5% vs 90.5%) compared to FCR

CONGRESS | #EHA2025 | PRESENTATION Paolo Ghia, Università Vita-Salute San Raffaele, Ospedale San Raffaele, presents the final analysis from the CAPTIVATE study of Ibr+Ven for CLL/SLL (N=202, FD cohort n=159; MRD cohort n=43). 5.5-year PFS=66% and OS=97%. In the FD cohort, 5.5-year PFS among patients without vs

#destacadoSEHH | España lidera un estudio pionero con epcoritamab para mejorar el abordaje del linfoma B de células grandes GELTAMO AbbVie España Hematología HGUGM Vall d'Hebron Mariana Bastos, MD, PhD Pau Abrisqueta Alejandro Martín García-Sancho immedicohospitalario.es/noticia/51673/… a través de IM Médico

GELTAMO en #18ICML CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS: A MULTICENTER STUDY FROM THE SPANISH GROUP GELTAMO Pau Abrisqueta International Conference on Malignant Lymphoma

David Russler-Germain, MD/PhD - fantastic work on LymphomaMAPs (microenv of DLBCL) looking at prognosis of CAR-T therapy. Showed that TEX archetype associated with signif worse outcome. Assoc with • exhausted T-cells • super-activated macrophages. #ICML18

Bispecifics in the frontline? In EPCORE NHL-5, Epcoritamab + pola-R-CHP in 1L DLBCL: – ORR 100%, CRR 97% – 81% MRD– by C3D1 (ctDNA!) Durable, deep responses. No ICANS. All CRS low grade. #ICML2025 #18ICML #lymsm

#18 ICML Lugano. Ana C Oliveira presenting data pn BTKi discontinuation in CLL patients on behalf of @GELLC

Best slide of #18ICML #ICML2025! COO/Dark signature #DLBCL. Magisterial Gianni Bonadonna lecture by Dr. David Scott from BCC. It was like a “Great Gig in the sky” realizing how far we have achieved in this #lymphoma. Only a matter of “Time” to be out of the eclipse “….

How we translate a genomic classification into treatment! #ICML2025 #18ICML

Philippe Giguère BC Cancer Ash Alizadeh, MD/PhD 🇺🇸 Adam Raymakers David Russler-Germain, MD/PhD International Conference on Malignant Lymphoma Here’s an updated version of our table - in addition the POLARIX Asian extension cohort found the same thing, plus our observational cohort of >700 patients presented at ASH. So 11/12 studies (7/8 trials, POLARGO being the first exception) show the same trend #18ICML

CONGRESS | #18ICML | PRESENTATION Allison M. Winter Allison Winter Taussig Cancer Institute Cleveland Clinic MD Cleveland Clinic shares results from a real-world study of axi-cel in patients with RT-LBCL (N = 91). In the largest study of real-world patients with RT treated with

Very proud 😊😊 of all the #Spanish faculty and fellow representation at #MCCR25 Fundación Jiménez Díaz Vall d’Hebron Institute of Oncology (VHIO) Hospital 12 Octubre The START Center and others… 🫶 SEOM

CONGRESS | #18ICML | PRESENTATION Kate Cwynarski Kate Cwynarski UCLH presents 7-year follow-up results from the phase II MARIETTA trial of multi-agent chemotherapy with MATRix and R-ICE followed by TT-ASCT in patients with SCNSL (N = 75). Long-term follow-up results demonstrate